Perspective Therapeutics Q2 FY26 net loss widens to $26.8 million - CATX News | RalliesPerspective Therapeutics Q2 FY26 net loss widens to $26.8 million
C
CATX• Clinical and manufacturing updates
- VMT-α-NET treated 76 NET patients as of July 31; Phase 3 site activation targeted around year-end 2026, subject to regulatory feedback.
- Chicago manufacturing site completion expected in early 2027; cash expected to fund planned milestones and investments into late 2027.
Second-quarter results and cash position
- Perspective Therapeutics posted a 2Q 2026 net loss of USD 26.8 million, narrowing from USD 21.5 million a year earlier.
- R&D expense rose to USD 21.5 million from USD 16.6 million, while G&A expense edged up to USD 7.8 million from USD 7.7 million.
- Cash, cash equivalents, and short-term investments climbed to about USD 237 million at June 30, from about USD 145 million at Dec. 31.
•
